Hoesli Rebecca C, Orringer Daniel A, McHugh Jonathan B, Spector Matthew E
1 Department of Otolaryngology-Head and Neck Surgery, University of Michigan Health System, Ann Arbor, Michigan, USA.
2 Department of Neurosurgery, University of Michigan Health System, Ann Arbor, Michigan, USA.
Otolaryngol Head Neck Surg. 2017 Sep;157(3):448-453. doi: 10.1177/0194599817700388. Epub 2017 Apr 11.
Objective We aim to describe a novel, label-free, real-time imaging technique, coherent Raman scattering (CRS) microscopy, for histopathological evaluation of head and neck cancer. We evaluated the ability of CRS microscopy to delineate between tumor and nonneoplastic tissue in tissue samples from patients with head and neck cancer. Study Design Prospective case series. Setting Tertiary care medical center. Subjects and Methods Patients eligible were surgical candidates with biopsy-proven, previously untreated head and neck carcinoma and were consented preoperatively for participation in this study. Tissue was collected from 50 patients, and after confirmation of tumor and normal specimens by hematoxylin and eosin (H&E), there were 42 tumor samples and 42 normal adjacent controls. Results There were 42 confirmed carcinoma specimens on H&E, and CRS microscopy identified 37 as carcinoma. Of the 42 normal specimens, CRS microscopy identified 40 as normal. This resulted in a sensitivity of 88.1% and specificity of 95.2% in distinguishing between neoplastic and nonneoplastic images. Conclusion CRS microscopy is a unique label-free imaging technique that can provide rapid, high-resolution images and can accurately determine the presence of head and neck carcinoma. This holds potential for implementation into standard practice, allowing frozen margin evaluation even at institutions without a histopathology laboratory.
目的 我们旨在描述一种用于头颈癌组织病理学评估的新型无标记实时成像技术——相干拉曼散射(CRS)显微镜。我们评估了CRS显微镜区分头颈癌患者组织样本中肿瘤组织和非肿瘤组织的能力。研究设计 前瞻性病例系列。研究地点 三级医疗中心。研究对象与方法 符合条件的患者为经活检证实、未经治疗的头颈癌手术候选者,术前已同意参与本研究。从50名患者身上采集组织,在通过苏木精和伊红(H&E)染色确认肿瘤和正常标本后,有42个肿瘤样本和42个正常相邻对照样本。结果 H&E染色确认有42个癌标本,CRS显微镜将其中37个鉴定为癌。在42个正常标本中,CRS显微镜将40个鉴定为正常。这使得在区分肿瘤和非肿瘤图像时,灵敏度为88.1%,特异性为95.2%。结论 CRS显微镜是一种独特的无标记成像技术,能够提供快速、高分辨率的图像,并且可以准确确定头颈癌的存在。这在标准实践中具有应用潜力,即使在没有组织病理学实验室的机构也能进行冰冻切缘评估。